TG Therapeutics Inc

Latest Report Overview

TG Therapeutics Inc (TGTX) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $240 million with diluted EPS of $0.05 and net income of $8 million. Operating margin was 9.0%, and free cash flow was $39 million for the period. The strong revenue trajectory continues to be driven by increasing adoption and prescription growth of BRIUMVI, reinforcing the company's position in the highly competitive multiple sclerosis market. Management continues to prioritize commercial execution and market penetration while maintaining disciplined R&D spending to support clinical programs and lifecycle management for the product. Financial performance reflects ongoing scaling of commercial activities with operating margins of 9.0%, demonstrating the leverage inherent in their model. The balance sheet remains stable with cash reserves of $482.6 million, providing flexibility to support ongoing commercialization and potential pipeline development as the company balances growth initiatives with operational efficiency.

Key Takeaways for TG Therapeutics Inc

• Revenue growth remains strong at 70.3% YoY for Q2 2026, driven by sustained market adoption of BRIUMVI in the multiple sclerosis segment.
• The company demonstrated continued operational leverage, reporting net income of $7.8 million and positive operating cash flow of $39.3 million for the quarter.
• Management has maintained consistent investment in R&D, with Q2 2026 R&D spend reaching $95.3 million to support future clinical pipeline development.
• The company's balance sheet remains solid with $482.6 million in cash, providing runway for commercial activities and potential strategic initiatives.
• Concentration risk persists as the company's growth is heavily tied to the successful commercialization of a single key product, BRIUMVI.
• Increased competition in the MS therapeutic space from entrenched incumbents remains a significant long-term challenge to sustaining high growth rates.

What Does TG Therapeutics Inc Do?

TG Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company's primary commercial asset is BRIUMVI (ublituximab), a CD20-depleting monoclonal antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). The company serves the healthcare market by targeting patients suffering from chronic autoimmune conditions, primarily working with healthcare providers and neurologists specializing in multiple sclerosis. Operating primarily in the United States, the company leverages its specialized sales and marketing force to drive adoption in major hospital and clinic networks, aiming to provide differentiated therapy options in a crowded therapeutic landscape.

Growth Drivers for TG Therapeutics Inc

• Continued market share expansion of BRIUMVI within the adult relapsing multiple sclerosis (RMS) patient population.
• Increased penetration into hospital and outpatient infusion center networks through focused sales efforts.
• Potential for label expansion or additional indications for existing assets within the B-cell disease portfolio.
• Enhanced payer coverage and reimbursement access to broaden patient eligibility and reduce barriers to therapy initiation.
• Strategic R&D investment directed at pipeline optimization and next-generation therapeutic development.